Contact information
michael.desborough@linacre.ox.ac.uk
michael.desborough@ouh.nhs.uk
Department of Clinical Haematology, Churchill Hospital, Oxford, OX3 9DU
He/Him
Colleges
Michael Desborough
BMedSci(Hons), MB ChB, FRCP, FRCPath, DPhil
Consultant Haematologist & Associate Professor of Haematology
The main focus of my research is assessing whether desmopressin could be used for treatment of thrombocytopenia or platelet dysfunction.
Platelets are a key part of clot formation. Patients with too few platelets, or platelets which are dysfunctional, are vulnerable to bleeding. One way to treat these patients is by transfusing platelets from a blood donor but this approach is often not effective. I am aiming to determine if desmopressin (a drug which increases platelet adhesion by stimulating release of Von Willebrand Factor) could be an effective adjuvant, or alternative treatment.
I am using a combination of methods to assess the value of desmopressin in this setting including meta-analysis of randomised controlled trials; laboratory assessment of thrombus formation under flow; and observational trials. I am leading two randomised placebo-controlled feasibility trials: desmopressin for prevention of bleeding in thrombocytopenia (DRIVE) and desmopressin for treatment of stroke due to haemorrhage (DASH).
Key publications
-
Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
Journal article
Desborough MJR. et al, (2023), Lancet Neurol, 22, 557 - 567
-
Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials.
Journal article
Odutayo A. et al, (2017), Lancet Gastroenterol Hepatol, 2, 354 - 360
-
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
Journal article
Thomas W. et al, (2021), J Thromb Haemost
-
Drug-induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data.
Conference paper
Schofield J. et al, (2022), Br J Haematol
-
Real-World Evidence of Caplacizumab Use in the Management of Acute TTP.
Journal article
Dutt T. et al, (2020), Blood
Recent publications
-
Myocardial iron intake following intravenous iron therapy with ferric carboxymaltose is sustained at 1 year despite recurrence of iron deficiency.
Journal article
Piechnik SK. et al, (2024), Br J Haematol
-
Transfusion Camp: The UK experience and its value in improving knowledge of transfusion medicine among postgraduate trainees.
Journal article
Aggarwal A. et al, (2024), Transfus Med
-
Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.
Journal article
Vera-Aviles M. et al, (2024), Eur Heart J
-
Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage.
Journal article
Eilertsen H. et al, (2023), Cochrane Database Syst Rev, 10
-
Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial.
Journal article
Desborough MJR. et al, (2023), Lancet Neurol, 22, 557 - 567
ORCID
0000-0002-1951-5616